目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary sources
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key primary sources
2.1.2.2 Objectives of primary research
2.1.2.3 Key data from primary sources
2.1.2.4 Breakdown of primaries
2.1.2.5 Key insights from primaries
2.2 MARKET SIZE ESTIMATION
2.2.1 REVENUE SHARE ANALYSIS
2.2.2 BOTTOM-UP APPROACH (SUPPLY-SIDE ANALYSIS)
2.2.3 TOP-DOWN APPROACH (UTILIZATION RATE AND ADOPTION PATTERN)
2.2.4 COMPANY PRESENTATIONS & PRIMARY INTERVIEWS
2.3 GROWTH FORECAST
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH IMITATIONS
2.6.1 SCOPE-RELATED LIMITATIONS
2.6.2 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 ELECTROPHYSIOLOGY MARKET OVERVIEW
4.2 NORTH AMERICA: ELECTROPHYSIOLOGY MARKET, BY PRODUCT AND COUNTRY
4.3 ELECTROPHYSIOLOGY MARKET: REGIONAL MIX
4.4 ELECTROPHYSIOLOGY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
4.5 ELECTROPHYSIOLOGY MARKET: EMERGING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Technological innovations for advanced, effective, and easy-to-use electrophysiological devices
5.2.1.1.1 Rising use of non-invasive cardiac mapping
5.2.1.1.2 Increasing use of improved intracardiac ablation systems
5.2.1.1.3 Rising use of MRI-guided ablation procedures
5.2.1.1.4 Increasing ultrasound guidance in electrophysiology labs
5.2.1.2 High geriatric population and increased prevalence of cardiovascular diseases
5.2.1.3 Rising investments, funds, and grants for cardiac surgeries and electrophysiology
5.2.1.4 Increasing cardiovascular disease incidence and procedural volume
5.2.2 RESTRAINTS
5.2.2.1 High product cost and inadequate reimbursement in developing and under-resourced healthcare settings
5.2.2.2 Unfavorable healthcare reforms in US
5.2.3 OPPORTUNITIES
5.2.3.1 Substantial growth opportunities in emerging economies
5.2.3.2 Popularity of ambulatory surgical centers offering cost-effective outpatient electrophysiology services
5.2.4 CHALLENGES
5.2.4.1 Global shortage of skilled and experienced personnel
5.3 INDUSTRY TRENDS
5.3.1 INTEGRATION OF DIGITAL TECHNOLOGIES, ARTIFICAL INTELLIGENCE, AND REMOTE MONITORING IN ELECTROPHYSIOLOGY
5.3.2 ROBOTIC-ASSISTED ABLATION AND NAVIGATION TECHNOLOGIES FOR BETTER TRACTION IN ELECTROPHYSIOLOGY
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 3D mapping and navigation systems
5.4.1.2 Cryoablation and radiofrequency ablation technologies
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Cardiac imaging technologies
5.4.2.2 Robotic navigation systems
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 AI-enabled intravascular optical coherence tomography (OCT)
5.4.3.2 AI-driven view guidance in intra-cardiac echocardiography (ICE)
5.5 PORTER'S FIVE FORCES ANALYSIS
5.5.1 INTENSITY OF COMPETITIVE RIVALRY
5.5.2 BARGAINING POWER OF BUYERS
5.5.3 BARGAINING POWER OF SUPPLIERS
5.5.4 THREAT OF SUBSTITUTES
5.5.5 THREAT OF NEW ENTRANTS
5.6 KEY STAKEHOLDERS & BUYING CRITERIA
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.6.2 KEY BUYING CRITERIA
5.7 REGULATORY ANALYSIS
5.7.1 REGULATORY FRAMEWORK
5.7.1.1 North America
5.7.1.1.1 US
5.7.1.1.2 Canada
5.7.1.2 Europe
5.7.1.3 Asia Pacific
5.7.1.3.1 Japan
5.7.1.3.2 China
5.7.1.3.3 India
5.7.1.4 Latin America
5.7.1.4.1 Brazil
5.7.1.5 Middle East & Africa
5.7.1.5.1 UAE
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 REIMBURSEMENT SCENARIO ANALYSIS
5.9 PATENT ANALYSIS
5.9.1 PATENT PUBLICATION TRENDS FOR ELECTROPHYSIOLOGY MARKET
5.9.2 LIST OF KEY PATENTS
5.10 TRADE ANALYSIS
5.10.1 IMPORT DATA FOR HS CODE 901890, 2020-2024
5.10.2 EXPORT DATA FOR HS CODE 901890, 2020-2024
5.11 PRICING ANALYSIS
5.11.1 INDICATIVE SELLING PRICE TREND OF ELECTROPHYSIOLOGY PRODUCTS, BY KEY PLAYER, 2022-2024
5.11.2 AVERAGE SELLING PRICE TREND OF ELECTROPHYSIOLOGY PRODUCTS, BY REGION, 2022-2024
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 UNMET NEEDS & END-USER EXPECTATIONS
5.14 VALUE CHAIN ANALYSIS
5.15 SUPPLY CHAIN ANALYSIS
5.16 ECOSYSTEM ANALYSIS
5.17 CASE STUDY ANALYSIS
5.17.1 JOHNSON & JOHNSON TO EXPAND CARTO SUITE AND LEVERAGE AI FOR DECISION SUPPORT, VISUALIZATION, AND REMOTE DATA SHARING
5.17.2 ABBOTT TO INTRODUCE ENSITE OMNIPOLAR TECHNOLOGY (OT) FOR ORIENTATION-INDEPENDENT MAPPING WITH PRECISE SIGNAL CLARITY
5.17.3 PHILLIPS TO LAUNCH KODEX-EPD SYSTEM FOR ENABLING HIGH-RESOLUTION ANATOMICAL AND ELECTRICAL MAPPING WITHOUT DIRECT CATHETER CONTACT
5.18 ADJACENT MARKET ANALYSIS
5.19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.20 INVESTMENT & FUNDING SCENARIO
5.21 IMPACT OF AI/GEN AI ON ELECTROPHYSIOLOGY MARKET
5.22 IMPACT OF 2025 US TARIFF ON ELECTROPHYSIOLOGY MARKET
5.22.1 KEY TARIFF RATES
5.22.2 PRICE IMPACT ANALYSIS
5.22.3 IMPACT ON COUNTRY/REGION
5.22.3.1 North America
5.22.3.1.1 US
5.22.3.2 Europe
5.22.3.3 Asia Pacific
5.22.4 IMPACT ON END-USE INDUSTRIES
5.22.4.1 Hospitals & clinics
5.22.4.2 Ambulatory surgery centers

6 ELECTROPHYSIOLOGY MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 ELECTROPHYSIOLOGY LABORATORY DEVICES
6.2.1 3D MAPPING SYSTEMS
6.2.1.1 Development of alternative technologies to limit market growth
6.2.2 ELECTROPHYSIOLOGY RECORDING SYSTEMS
6.2.2.1 Increasing public-private funding for developing advanced novel recording systems to augment market growth
6.2.3 RADIOFREQUENCY (RF) ABLATION SYSTEMS
6.2.3.1 Cost-effectiveness and technological advancements to spur segment growth
6.2.4 INTRACARDIAC ECHOCARDIOGRAPHY (ICE) ULTRASOUND IMAGING SYSTEMS
6.2.4.1 Rising lifestyle- and age-related disorders to drive adoption for cardiac disease treatment
6.2.5 ELECTROPHYSIOLOGY X-RAY SYSTEMS
6.2.5.1 High incidence of cardiovascular disorders and availability of technologically advanced equipment to boost market growth
6.2.6 REMOTE MAGNETIC & ROBOTIC NAVIGATION SYSTEMS
6.2.6.1 Favorable reimbursement scenario to propel market growth
6.3 ELECTROPHYSIOLOGY ABLATION CATHETERS
6.3.1 CRYOABLATION CATHETERS
6.3.1.1 Therapeutic advantages and better clinical studies to drive market growth
6.3.2 RADIOFREQUENCY (RF) ABLATION CATHETERS
6.3.2.1 Technologically-advanced and safer catheters to drive adoption among healthcare professionals
6.3.3 MICROWAVE ABLATION (MWA) CATHETERS
6.3.3.1 Smaller diameter antennas, faster procedure times, and larger heating zones to aid market growth
6.3.4 LASER ABLATION CATHETERS
6.3.4.1 Launch of technologically-advanced laser ablation catheters to drive adoption in healthcare settings
6.4 ELECTROPHYSIOLOGY DIAGNOSTIC CATHETERS
6.4.1 CONVENTIONAL ELECTROPHYSIOLOGY DIAGNOSTIC CATHETERS
6.4.1.1 Development of technologically-advanced fixed and steerable diagnostic catheters to favor market growth
6.4.2 ADVANCED ELECTROPHYSIOLOGY DIAGNOSTIC CATHETERS
6.4.2.1 Advanced electrophysiology diagnostic catheters to improve patient outcomes and optimize surgical procedures
6.4.3 ULTRASOUND ELECTROPHYSIOLOGY DIAGNOSTIC CATHETERS
6.4.3.1 Availability of advanced ultrasound catheters and focus on supportive regulatory frameworks to drive segment
6.5 ELECTROPHYSIOLOGY ACCESS DEVICES
6.5.1 LAUNCH OF ADVANCED ACCESS DEVICES TO ENHANCE EFFICIENCY DURING ABLATION CATHETER MAPPING AND POSITIONING
6.6 OTHER ELECTROPHYSIOLOGY PRODUCTS

7 ELECTROPHYSIOLOGY MARKET, BY INDICATION
7.1 INTRODUCTION
7.2 ATRIAL FIBRILLATION
7.2.1 DEVELOPMENT OF ADVANCED CARDIAC MAPPING SYSTEMS FOR EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
7.3 ATRIAL FLUTTER
7.3.1 HIGH SUCCESS RATE OF RADIOFREQUENCY CATHETER ABLATION FOR TREATING ATRIAL FLUTTER TO PROPEL MARKET GROWTH
7.4 ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA (AVNRT)
7.4.1 INCREASING EFFICACY OF ELECTROPHYSIOLOGY DEVICES FOR TREATMENT OF AVNRT TO AID MARKET GROWTH
7.5 WOLFF-PARKINSON-WHITE (WPW) SYNDROME
7.5.1 PREFERENCE FOR RADIOFREQUENCY ABLATION OVER SURGERY TO AUGMENT MARKET GROWTH
7.6 OTHER INDICATIONS

8 ELECTROPHYSIOLOGY MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS & CARDIAC CENTERS
8.2.1 PRESENCE OF BETTER CATHETERIZATION AND ELECTROPHYSIOLOGY LABORATORIES IN HOSPITALS TO SUPPORT MARKET GROWTH
8.3 AMBULATORY SURGERY CENTERS
8.3.1 DEMAND FOR MINIMAL HOSPITAL STAYS AND HIGH INCIDENCE OF CARDIOVASCULAR DISEASES TO FUEL MARKET GROWTH
8.4 OTHER END USERS

9 ELECTROPHYSIOLOGY MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 US to dominate North American electrophysiology market during forecast period
9.2.3 CANADA
9.2.3.1 Growing government research funding to support market growth
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Rising prevalence of atrial fibrillation and associated arrhythmias to propel market growth
9.3.3 UK
9.3.3.1 High geriatric population and rise in cardiac diseases to fuel market growth
9.3.4 FRANCE
9.3.4.1 Favorable government healthcare policies and schemes to support market growth
9.3.5 ITALY
9.3.5.1 Rising incidence of cardiovascular diseases to drive adoption of electrophysiology devices
9.3.6 SPAIN
9.3.6.1 Rising number of cardiac ablation procedures to drive adoption of electrophysoiology products
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 JAPAN
9.4.2.1 Favorable reimbursement scenario and presence of universal healthcare policies to boost market growth
9.4.3 CHINA
9.4.3.1 Growing geriatric population and rising prevalence of cardiovascular diseases to favor market growth
9.4.4 INDIA
9.4.4.1 Favorable government healthcare initiatives to support market growth
9.4.5 AUSTRALIA
9.4.5.1 Increasing target disease burden and rising government funding to spur market growth
9.4.6 SOUTH KOREA
9.4.6.1 Supportive government initiatives to drive market
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Modernization of healthcare facilities to propel market growth
9.5.3 MEXICO
9.5.3.1 Favorable investment scenario for medical device manufacturers to fuel market growth
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
9.6.2 GCC COUNTRIES
9.6.2.1 Kingdom of Saudi Arabia
9.6.2.1.1 Rising number of private hospitals and increasing government financial support to fuel market growth
9.6.2.2 UAE
9.6.2.2.1 High clinical demand, increased government investment, and technological progress to aid market growth
9.6.2.3 Rest of GCC Countries
9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ELECTROPHYSIOLOGY MARKET
10.3 REVENUE ANALYSIS, 2020-2024
10.4 MARKET SHARE ANALYSIS, 2024
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.5.5.1 Company footprint
10.5.5.2 Region footprint
10.5.5.3 Product footprint
10.5.5.4 Indication footprint
10.5.5.5 End-user footprint
10.6 COMPANY EVALUATION MATRIX, STARTUPS/SMES, 2024
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.6.5.1 Detailed list of key startups/SMEs
10.6.5.2 Competitive benchmarking of startups/SMEs
10.7 COMPANY VALUATION & FINANCIAL METRICS
10.7.1 FINANCIAL METRICS
10.7.2 COMPANY VALUATION
10.8 BRAND/PRODUCT COMPARISON
10.9 R&D ASSESSMENT OF KEY PLAYERS
10.10 COMPETITIVE SCENARIO
10.10.1 PRODUCT LAUNCHES & APPROVALS
10.10.2 DEALS
10.10.3 OTHER DEVELOPMENTS

11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 JOHNSON & JOHNSON SERVICES, INC.
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Product launches and approvals
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Right to win
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 ABBOTT
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Product launches
11.1.2.3.2 Deals
11.1.2.4 MnM view
11.1.2.4.1 Right to win
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 MEDTRONIC
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Product approvals
11.1.3.3.2 Deals
11.1.3.4 MnM view
11.1.3.4.1 Right to win
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses & competitive threats
11.1.4 KONINKLIJKE PHILIPS N.V.
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Deals
11.1.4.4 MnM view
11.1.4.4.1 Right to win
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses & competitive threats
11.1.5 GE HEALTHCARE
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 Recent developments
11.1.5.3.1 Product approvals and enhancements
11.1.5.3.2 Deals
11.1.5.4 MnM view
11.1.5.4.1 Right to win
11.1.5.4.2 Strategic choices
11.1.5.4.3 Weaknesses & competitive threats
11.1.6 BOSTON SCIENTIFIC CORPORATION
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Product approvals
11.1.6.3.2 Deals
11.1.7 JAPAN LIFELINE CO., LTD.
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.8 STEREOTAXIS, INC.
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Product approvals
11.1.8.3.2 Deals
11.1.9 MICROPORT SCIENTIFIC CORPORATION
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.9.3 Recent developments
11.1.9.3.1 Product approvals
11.1.9.3.2 Other developments
11.1.10 BIOTRONIK
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Expansions
11.1.11 TELEFLEX INCORPORATED
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Deals
11.1.12 ACUTUS MEDICAL, INC.
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.12.3 Recent developments
11.1.12.3.1 Product approvals
11.1.13 MERIT MEDICAL SYSTEMS
11.1.13.1 Business overview
11.1.13.2 Products offered
11.1.13.3 Recent developments
11.1.13.3.1 Deals
11.1.14 OSYPKA MEDICAL
11.1.14.1 Business overview
11.1.14.2 Products offered
11.1.15 COOK
11.1.15.1 Business overview
11.1.15.2 Products offered
11.2 OTHER PLAYERS
11.2.1 EPMAP-SYSTEM
11.2.2 CATHRX LTD.
11.2.3 EP SOLUTIONS
11.2.4 CATHVISION
11.2.5 TZ MEDICAL, INC.
11.2.6 APN HEALTH, LLC
11.2.7 LEPU MEDICAL TECHNOLOGY (BEIJING) CO.,LTD.
11.2.8 CARDIOFOCUS
11.2.9 SCHWARZER CARDIOTEK
11.2.10 IMRICOR

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS